Evaluation of omega-3 oral supplementation effect on intraocular pressure

Effect of oral omega-3 supplementation on intraocular pressure in normotensive adults referring to ophthalmology clinics of Golestan University of Medical Sciences

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201011048989N1

Enrollment

Registered

2020-11-14

Start date

2020-10-11

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraocular pressure.

Interventions

Intervention group: For all patients, omega-3 supplements will be prescribed daily for one omega-3 oral capsule of Minoo Pharmaceutical Company containing 1000 mg of omega-3 and 180 mg of echopentanoi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients aged 18 years and older Satisfaction to participate in the study No contraindications to the use of omega-3 supplements in patients Do not take drugs that affect the lipid profile in the study Normal intraocular pressure (less than 21)

Exclusion criteria

Exclusion criteria: Lack of follow-up of patients during the study period Not interested in participating in the study History of intraocular surgery The need for intraocular surgery, including glaucoma surgery during the study period People who have to stop or not continue omega 3 due to the need for surgery People who have been prescribed more therapeutic doses of omega-3s due to an nutritional illness People who have taken omega-3 supplements before studying Taking drugs that affect lipid profile during the study Intraocular pressure above 21 Previous diagnosis of glaucoma Having angle-closure glaucoma

Design outcomes

Primary

Measure	Time frame
Intraocular pressure. Timepoint: Measurement of intraocular pressure at the beginning of the study and 90 days after starting omega 3 supplementation. Method of measurement: Goldmann applanation tonometry.	—

Secondary

Measure	Time frame
Body mass index. Timepoint: At beginning of the study. Method of measurement: Weight in kilograms divided by height squared in meters.;Blood pressure. Timepoint: At the beginning of the study. Method of measurement: Hand barometer.;Fasting blood sugar. Timepoint: At the beginning of the study. Method of measurement: Blood test.;Triglyceride. Timepoint: At the beginning of the study. Method of measurement: Blood test.;High-density lipoprotein cholesterol. Timepoint: At the beginning of the study. Method of measurement: Blood test.	—

Measure

Time frame

Body mass index. Timepoint: At beginning of the study. Method of measurement: Weight in kilograms divided by height squared in meters.;Blood pressure. Timepoint: At the beginning of the study. Method of measurement: Hand barometer.;Fasting blood sugar. Timepoint: At the beginning of the study. Method of measurement: Blood test.;Triglyceride. Timepoint: At the beginning of the study. Method of measurement: Blood test.;High-density lipoprotein cholesterol. Timepoint: At the beginning of the study. Method of measurement: Blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarjan Akbari Kamrani

Gorgan University of Medical Sciences

dr.kamrani@goums.ac.ir+98 17 3116 3354

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026